Skip to main content
Caplight Logo









NephroPlus

NephroPlus

Public
Hyderabad, TelanganaHealthcare/Wellnesshttps://nephroplus.com

NephroPlus is now publicly traded

The data on this page reflects NephroPlus's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Dec 10, 2025

Last Round

Series F

May 3, 2024

Est. Valuation at Exit

$240.38M

Total Funding Raised

$314.16M

Company Overview

NephroPlus operates in Healthcare/Wellness and is based in Hyderabad, Telangana. It has raised $314.16M.

NephroPlus is a healthcare company that operates a network of dialysis centers providing high-quality and affordable dialysis services, along with treatments for kidney and urological issues through standardized protocols and continuous innovation.

Sector

Healthcare/Wellness

AI Layer

Application

NephroPlus Comparables

Compare NephroPlus with similar companies based on industry and business-model similarity.

NephroPlus comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
The Renal Project
72%
Médica Santa Carmen
67%
Moolchand Healthcare
46%
Book a demo to see all comparables

For institutional investors. Book with your work email.

NephroPlus Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPODec 10, 2025
Series FMay 3, 2024
DebtDec 19, 2022
Series EDec 13, 2021
Series DNov 25, 2019
Series C
Aug 24, 2016
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Rohit Singh

Group Chief Executive Officer

Executive Team

Sreeja Dey

Chief Executive Officer

Executive Team

Sukaran Saluja

Chief Executive Officer - India Nepal

Executive Team

Naga Sumedh Desu

AGM - Finance Excellence and CFO Office

Executive Team

For institutional investors. Book with your work email.

NephroPlus Investors

Notable investors and investment history

NephroPlus investors
InvestorRounds
SCPSeries E
Baroda BNP Paribas Mutual FundIPO
Polar CapitalIPO
Prudential Assurance CompanyIPO
DSP Mutual FundIPO
InvestcorpIPO, Series F, Series E, Series D
International Finance CorporationSeries D, IPO, Series C, Series F, Series B
Book a demo to see all 24 investors

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • expands_offices_inNov 12, 2026

    NephroPlus plans to expand its dialysis clinic network across India in FY27, targeting 40–50 additional clinics for the full financial year.

  • has_revenueNov 5, 2026

    In H1FY27, NephroPlus reports $61.8M in revenue from its dialysis clinic network, up 23.6% year-on-year.

  • opens_new_locationNov 5, 2026

    NephroPlus is excited to open NephroPlus in Kazakhstan, using two acquired clinics as a starting point for scaling its network in the country.

  • launchesSep 11, 2026

    NephroPlus launches the International Dialysis Academy at its standalone dialysis centre in Hyderabad, India, to prepare nursing graduates in India and the Philippines for specialized dialysis-care careers and international deployment.

  • opens_new_locationAug 28, 2026

    NephroPlus opens a new dialysis center in Mindanao as part of three new centers that expand access to patient-centered hemodialysis care on Aug 28th '26.

Book a demo to see all news

For institutional investors. Book with your work email.

NephroPlus Filings

Explore SEC and related filing metadata, where available.

NephroPlus filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Firmographic Details

HeadquartersHyderabad, Telangana
Employee Range2,096
Year Founded2010
Last FundingMay 3, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?